717 Selective activation of CD8+ T cells by a CD8-targeted IL-2 results in enhanced anti-tumor efficacy and safety

• Wei Chen,
• Ton Schumacher,
• Ivana Djuretic,
• Irene Ni,
• Paul Bessette,
• Kelly Moynihan,
• Danielle Pappas,
• Terrence Park,
• Mike Chin,
• Andy Yeung

Affiliations

Wei Chen

Department of Rehabilitation Medicine, XuZhou Central Hospital, Xuzhou, Jiangsu, China

Ton Schumacher

Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, The Netherlands

Ivana Djuretic

Aff1 Celgene Cellular Therapeutics Warren NJ USA

Irene Ni

Pfizer Cancer Immunology Discovery, Pfizer Inc, San Diego, California, USA

Paul Bessette

Department of Obstetrics and Gynecology, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada

Kelly Moynihan

2MIT, Cambridge, MA, USA

Danielle Pappas

1Asher Biotherapeutics, South San Francisco, CA, United States

Terrence Park

1Asher Biotherapeutics, South San Francisco, CA, United States

Mike Chin

1Asher Biotherapeutics, South San Francisco, CA, United States

Andy Yeung

1Asher Biotherapeutics, South San Francisco, CA, United States